Flumazenil 0,5 Mg/5 Ml Fresenius & Flumazenil 1,0 Mg/10 Ml Fresenius 0,5 mg/5 mL AND 1,0 mg/10 mL Solution for injection/infusion
PDF Leaflet Revision Date: 12 July 2022
Clinical Summary
Quick overview from the medicine insert
Indication
Reversal of benzodiazepine sedation and overdose.
Dosage (summary)
Initial dose: 0.2 mg IV over 15 seconds; max total dose: 1 mg.
Onset of Action / Duration
Onset: 1-2 mins, Duration: variable.
Special Populations
- Hepatic impairment
Pregnancy & Breastfeeding
Safety not established; breastfeeding should be interrupted for 24 hours.
Key Drug Interactions
- Benzodiazepines
- Tricyclic antidepressants
Contraindications
- Hypersensitivity to flumazenil
- Benzodiazepines for life-threatening conditions
Common side effects
- Anxiety
- Palpitations
- Nausea
- Headache
Counselling Points
- Monitor for re-sedation
- Avoid hazardous activities for 24 hours
- Report any adverse reactions
Serious warnings
- Risk of re-sedation
- Seizures in epileptic patients
- Monitor for respiratory depression
Important Disclaimer
The Flumazenil 0,5 Mg/5 Ml Fresenius & Flumazenil 1,0 Mg/10 Ml Fresenius 0,5 mg/5 mL AND 1,0 mg/10 mL Solution for injection/infusion professional information leaflet below is the property of Fresenius Kabi South Africa and is provided on Medinsert exactly as issued, with no.. alterations or editorial changes. We make every effort to keep content current by updating documents as soon as new versions become available. Medinsert serves as a trusted access point for healthcare professionals, but does not replace official sources or clinical judgement. For more details, please read our full disclaimer. read more>>
Healthcare Professionals Only
This content is for registered healthcare professionals
Sign in or create a free account to read the full package insert.
Free for HPCSA-registered professionals. Powered by Medinsert.
